Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 22, 2026, 1:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–27 of 3 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: MN Clear all

Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults

NCT00001052

View directory record Official record

Conditions: HIV Infections
Interventions: Aluminum hydroxide, QS-21, rgp120/HIV-1MN; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years

Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1997
U.S. locations: 5
States / cities: St Louis, Missouri • Rochester, New York • Pittsburgh, Pennsylvania + 2 more

Source: ClinicalTrials.gov public record

Updated Nov 3, 2021 · Synced May 22, 2026, 1:38 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Trial To Evaluate the Safety and Immunogenicity of the UBI HIV-1MN PND Peptide Immunogen, Given by IM Injection, in Combination With the UBI Microparticulate Monovalent HIV-1 MN Branched Peptide Given Orally, in HIV-1 Uninfected Volunteers.

NCT00000846

View directory record Official record

Conditions: HIV Infections
Interventions: HIV-1 Peptide Vaccine, Microparticulate Monovalent, HIV-1 Peptide Immunogen, Multivalent; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years

Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 3
States / cities: Birmingham, Alabama • Rochester, New York • Seattle, Washington

Source: ClinicalTrials.gov public record

Updated Jun 23, 2005 · Synced May 22, 2026, 1:38 AM EDT

Recruiting No phase listed Observational

Nephrotic Syndrome Study Network

NCT01209000

View directory record Official record

Conditions: Minimal Change Disease (MCD), Membranous Nephropathy, Glomerulosclerosis, Focal Segmental
Interventions: Kidney Biopsy; Procedure
Lead sponsor: University of Michigan; Other
Eligibility: Up to 80 Years

Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2029
U.S. locations: 39
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 26 more

Source: ClinicalTrials.gov public record

Updated Apr 23, 2025 · Synced May 22, 2026, 1:38 AM EDT